entertainment -WSS

entertainment

author：leisure time 2025-09-05 09:20:07 - browse：45741

George Yancopoulos on the 2024 Breakthrough Summit East stage. — George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

George Yancopoulos is in touch with his teenage self.

After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

“My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： EU regulator recommends expanding Mounjaro approval to obesity

WSS

Why Eli Lilly’s earnings didn’t quite live up to the hype

Too many hospitalized Covid

Elizabeth Holmes banned from government health programs

Think you might have Covid

Test for long Covid? Researchers find new clue in blood samples

FDA clears AI tool for detecting skin cancer

focus

entertainment

explore

Alkermes shareholders re

NIH director takes cautious approach to Biden drug pricing priority

Medical leaders decry Supreme Court decision on affirmative action

Abbott's new heart device gets FDA advisory panel nod

State Dept. review finds Biden bears some blame for Afghanistan failures

New brain studies show LSD's effects on the brain in full color

Apple is now the first public company to be valued at $3 trillion

Humana cuts profit projections as Medicare Advantage costs soar

State Dept. review finds Biden bears some blame for Afghanistan failures

AI generated plenty of interest at JPM but not a lot of trust

knowledge

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Dewpoint Therapeutics lays off staff after losing partnerships

EU regulator recommends expanding Mounjaro approval to obesity

Doctors on social media are being harassed and cyberbullied

My yearlong odyssey to get my son’s ADHD medication covered

Bernie Sanders gets little from pharma CEOs on drug prices

explore

hotspot

Wikipedia

hotspot